Chitinase 3-like 1, otherwise known as YKL-40, is a secreted glycoprotein purported to have a role in extracellular matrix metabolism. The first mammalian cell type found to express YKL-40 was the human osteosarcoma-derived osteoblast, MG63. In that first study the active vitamin D3 metabolite, 1,25-dihydroxycholecalciferol (1,25D), stimulated YKL-40 expression, thereby indicating that a vital factor for skeletal health promoted YKL-40 synthesis by bone forming cells. However, when these MG63 cells were exposed to 1,25D they were also exposed to serum, a rich source of the pleiotropic lipid mediator, lysophosphatidic acid (LPA). Given that 1,25D is now known to co-operate with selected growth factors, including LPA, to influence human osteoblast differentiation we 
Introduction
Located on the long arm end of chromosome 1, 1q31-q32, is CHI3L1, the gene encoding YKL-40 [1, 2] , otherwise known as chitinase 3-like 1 (CHI3L1), breast regression protein 39 (BRP-39, murine analog) or human cartilage glycoprotein 39 (HC-gp39). Originally identified in the whey fraction of non-lactating cows [3] it is a secreted glycoprotein of the 18-glycosylhydrolase family. The term YKL-40 is attributed to its apparent molecular mass of 40kDa and the N-terminal amino acids tyrosine (Y), lysine (K) and leucine (L). Although chitinase-like, YKL-40 does not exhibit glycohydrolase activity because an essential active site glutamate and juxtaposed aspartate residue are replaced with a leucine and alanine residue respectively. Devoid of chitinase activity the glycoprotein is still able to bind chitin and chitooligosaccharides with high affinity because a hydrophobic substrate binding cleft is present [3] [4] [5] . To date the precise biological function(s) of YKL-40 remains elusive but it is thought to have a connection with extracellular matrix (ECM) remodelling in both health and disease [6, 7] . Indeed, there are instances of raised YKL-40 production where there is tissue damage, inflammation and ECM pathology, for example, liver fibrosis, rheumatoid arthritis, osteoarthritis and sarcoidosis [8, 9] .
The discovery that YKL-40 binds to fibrillar collagens I-III and can influence collagen fibril formation could indeed support a role of YKL-40 in connective tissue formation and/or turnover. The first mammalian cell type found to mobilise YKL-40 was the human immature osteoblast cell line, MG63 [10] . Since then it has emerged that YKL-40 is expressed by human osteoblasts and osteocytes at both endochondral and intramembranous sites of ossification [11, 12] perhaps lending credence to a role of YKL-40 in bone development. In the context of bone metabolism in disease are the (compelling) reports of raised YKL-40 in the serum and synovial fluid from patients presenting with osteoarthritis [13] [14] [15] , a crippling affliction of which bone composition and turnover are often markedly affected [16] [17] [18] [19] .
Connor and colleagues [11] initially postulated that raised YKL-40 expression in the serum and synovial fluid from patients with osteoarthritis may be a feature of heightened bone formation in affected joints. Bone tissue is a composite of highly tensile type I collagen fibers impregnated with hydroxyapatite imparting material stiffness. Osteoblasts are responsible for the provision of this matrix, an activity under the regulation of multiple local and systemic soluble factors. How these agents influence osteoblast YKL-40 is largely unknown. However there is an indication that the active metabolite of vitamin D3, 1,25-dihydroxycholecalciferol (1,25D), might stimulate YKL-40 production following the finding of the glycoprotein in the conditioned media of cultured MG63 cells exposed to 1,25D [10] .
Interestingly in their study, Johansen and colleagues [10] treated MG63 cells with 1,25D in growth medium supplemented with foetal calf serum, a rich source of the pleiotropic growth factor, lysophosphatidic acid (LPA), as bound to the albumin fraction [20, 21] . In the context of human osteoblast biology we now know LPA to cooperate synergistically with 1,25D in stimulating increased production of tissue nonspecific alkaline phosphatase (TNSALP) [22] [23] [24] [25] , an enzyme essential for bone collagen mineralisation [26] and a marker of the mature osteoblast phenotype [27] .
There is a growing interest in LPA in skeletal biology [23] but whether it has a role in the expression of YKL-40 in bone cells has not been forthcoming. Indeed at the time of this particular study there were no published works reporting on YKL-40 expression in response to LPA/related analogues for any mammalian cell type. Given that LPA, like YKL-40, is implicated in tissue repair, remodelling and fibrosis [28] [29] [30] we sought to investigate if LPA 4 could stimulate human osteoblast YKL-40 expression and how 1,25D might influence this.
Herein we provide evidence that LPA can stimulate YKL-40 production. Importantly the costimulation of osteoblasts with LPA and 1,25D culminated in a synergistic increase in YKL-40 mobilisation. Our findings offer new insights into the molecular control of osteoblast in the context of 1,25D and LPA-induced cellular differentiation.
Materials & Methods

General
Unless stated otherwise, all reagents were of analytical grade from Sigma-Aldrich (Poole, UK). Stocks of LPA (10mM, Enzo Life Sciences, Exeter, UK) were prepared in 1:1 ethanol:tissue culture grade water and stored at -20 °C. Likewise, 100 μM stocks of 1,25D and 24,25D (both epimers) were prepared in ethanol and stored at -20 °C. The vitamin D receptor (VDR) ligands delphinidin chloride (Del) and lithocholic acid acetate methyl ester (LCA Ac Ome, Steraloids, INc. Rhode Island, US) were reconstituted to 10 and 5mM respectively in ethanol and curcumin (CM, Tocris, Bristol, UK) stocks (10mM) prepared using DMSO. The LPA1/3 receptor antagonist, Ki16425, was reconstituted to 20mM in DMSO and stored at -20 °C. The specificity protein 1 (Sp1) inhibitor, mithramycin A, was prepared as a 500M stock in ethanol; the activator protein-1 (AP-1) inhibitor, SR11301 (Tocris, Bristol, UK) was reconstituted to 10mM in ethanol, as were inhibitors to both MEK (UO126, Merck Serono Ltd, Feltham, UK) and Stat3 (S31-201, Merck Serono Ltd, Feltham, UK). The protein kinase C activator, phorbol 12-myristate 13-acetate (PMA) was supplied by Tocris (Bristol, UK) and prepared as a 50g/ml stock in ethanol. In each case all reagent stocks were aliquoted and stored at -20 °C.
Human osteoblasts
Human osteoblast-like cells (MG63) were cultured in conventional tissue culture flasks (250 mL, Greiner, Frickenhausen, Germany) in a humidified atmosphere at 37 °C and 5 % CO2.
Although osteosarcoma-derived, MG63 cells exhibit features in common with human osteoblast precursors or poorly differentiated osteoblasts. Specifically, these cells produce type I collagen with no or low basal osteocalcin (OC) and alkaline phosphatase (ALP).
However, when MG63 s are treated with 1,25D, OC expression increases [31, 32] and, when the same cells are co-treated with 1,25D and selected growth factors, e.g. LPA, the levels of ALP markedly increase [22] , a feature of the mature osteoblast phenotype. Consequently, the application of these cells to assess the potential pro-maturation effects of selected factors is entirely appropriate. Cells were grown to confluence in Dulbecco's modified Eagle medium (DMEM)/F12 nutrient mix (Gibco, Paisley, Scotland) supplemented with sodium pyruvate (1 mM final concentration), L-glutamine (4 mM), streptomycin (100 ng/mL), penicillin (0.1 units/mL) and 10 % v/v foetal calf serum (Gibco, Paisley, Scotland). The growth media (500 mL final volume) was also supplemented with 5 mL of a 100x stock of non-essential amino acids. Once confluent, MG63s were subsequently dispensed into blank 24-well plates (Greiner, Frickenhausen, Germany). In each case, wells were seeded with 1 mL of a 2 x 10 4 cells/mL suspension (as assessed by haemocytometry). Cells were then cultured for 3 days, the media removed and replaced with serum-free DMEM/F12 (SFCM) to starve the cells overnight. Osteoblasts were subsequently treated with 1,25D (100nM), LPA (1.25-10M) or a combination of these factors in the presence and absence of selected inhibitory compounds. An examination of LPA (10M) in combination with either DC, CM (10M) or LCA Ac Ome (5M) was also investigated. Similarly the influence of PMA (50ng/ml) in combination with 1,25D (100nM) on YKL-40 expression was also ascertained. In each instance MG63 cells were treated with phenol red-free serum free culture medium to eliminate any interference with the assays described below. After the desired time point (24-72hr) the conditioned media were processed for YKL-40 quantification (see below) and the remaining monolayers processed for cell number and total ALP activity to ascertain the extent of cellular growth and maturation respectively.
Chitinase 3-like 1 (YKL-40) quantification in conditioned media
The quantification of YKL-40 in cell culture media was performed using a proprietary ELISA 
Cell number
An assessment of cell number was performed using a combination of the tetrazolium rpm to pellet the cells and 0.1 mL of the supernatants dispensed onto a 96-well microtitre plate and the absorbances read at 492 nm using a multiplate reader. Plotting the absorbances against known cell number, as assessed initially using haemocytometry, enabled extrapolation of cell numbers for the experiments described herein.
Total ALP activity
An assessment of ALP activity is reliably measured by the generation of p-nitrophenol (p-NP) from p-nitrophenylphosphate (p-NPP) under alkaline conditions. The treatment of cells to quantify ALP activity was similar to that described by us recently [17] . Briefly, the MTS/PMS reagent was removed and the monolayers incubated for a further 5 min in fresh phenol redfree DMEM/ F12 to remove the residual formazan. Following this incubation period, the medium was removed and the monolayers lysed with 0.1 mL of 25 mM sodium carbonate from the MTS/PMS assay described above. 
Expression of YKL-40 via quantitative PCR
Statistical analysis
Unless stated otherwise, all the cell culture experiments described above were performed three times and all data were subject to a one-way analysis of variance (ANOVA) to test for statistical significance as we have reported previously [33] . When a p value of < 0.05 was found, a Tukey multiple comparisons post-test was performed between all groups. All data are expressed as the mean together with the standard deviation.
Results
Co-treating MG63 cells with LPA and 1,25D stimulates a synergistic increase in YKL-40 expression.
As reported by us previously the application of 1,25D (100nM) resulted in a modest decrease in MG63 cell number (p<0.01) which is in keeping with a pro-differentiating effect of this secosteroid. In contrast treating these cells with LPA (10M) led to the expected increase in cell growth (p<0.01) when compared to medium controls (Fig. 1A) . Co-treating MG63 cells with LPA and 1,25D led to the expected differentiation response as supported by a clear, synergistic increase in total ALP activity (p<0.001) compared to all other groups (Fig.   1B) . The conditioned medium harvested from co-stimulated cells was found to have markedly elevated levels (66 ± 10 ng/ml per 100k cells, p<0.01) of YKL-40 ( In a previous study we found that Ki16425 (10M), an inhibitor of LPA1/LPA3 receptors, blunted the expression of ALP from cells co-stimulated with LPA and 1,25D [22] . Herein we find that the same inhibitor markedly supressed (~ 8 fold, p<0.001) the expression of YKL-40
for co-treated cells; 234.5 ± 20.8 versus 28.9 ± 2.3 ng/ml per 100k cells (Fig. 3A) . As anticipated the application of Ki16425 inhibited expression of ALP from co-treated cells (Fig.   3B ).
The VDR ligands 24,25D and LCA Ac Ome also co-operate with LPA to enhance YKL-40
expression by MG63 cells.
In addition to 1,25D we found that another dihydroxylated metabolite of vitamin D3, namely 24,25D (100nM), co-operated with LPA (10M) in stimulating YKL-40 production by cultured MG63 cells (Fig. 4A) . Both epimers were functional with 24R,25D being modestly more potent ( ** p<0.01) than 24S,25D. Another bone fide agonist of the VDR, LCA Ac Ome, also converged with LPA to increase the levels ( * p<0.001 compared to agents in isolation) of YKL-40 in the conditioned media (Fig. 4B) . With regard to the purported VDR ligands, CM and Del, both compounds were found not to act with LPA in promoting YKL-40 expression (data not shown).
The phorbol ester PMA converges with 1,25D in stimulating MG63 YKL-40 production.
We previously found that the protein kinase C activator, PMA, co-operated with 1,25D to bolster MG63 ALP activity [34] but whether this agent pairing might also influence YKL-40 production was not explored. In isolation both PMA and 1,25D had little, if any, effect on YKL-40 expression but when administered together there was a stark, synergistic, increase ( * p<0.001) in the levels of YKL-40 in the conditioned media following three days of culture (Fig. 5) .
Discussion
Following the discovery of YKL-40 in the conditioned medium of cultured (MG63)
osteoblasts [10] studies began focussing on YKL-40 expression in the context of degenerative joint disease. It soon emerged that the levels of this glycoprotein were substantially elevated in the synovial fluid and serum from patients with either osteoarthritis or rheumatoid arthritis [13] [14] [15] . These findings suggested that YKL-40 might be a valuable marker and/or prognostic for degenerative joint disease. Since then there has been a rapid expansion of studies examining YKL-40 amongst a plethora of anomalies ranging from Alzheimer's disease [35] to ulcerative colitis [36] . Throughout this time, and despite the wealth of studies being reported, how YKL-40 expression might be regulated by local and systemic factors has received scant attention. Indeed this was raised recently by Bhardwaj and co-workers [37] wherein the authors state: "Despite the numerous reports documenting elevated expression of YKL-40, relatively little is known about the inflammatory mediators and specific molecular mechanisms that control its expression."
In the context of 1,25D-induced osteoblast maturation it was of notable interest to see that MG63 cells exposed to this steroid produced greater quantities of YKL-40 into the surrounding growth medium [10] . These initial findings support the possibility that YKL-40 may in some way be linked to the provision of a mature mineralised bone matrix given that 1,25D deficiency results in childhood rickets and osteomalacia in adults [26] . With regard to the range of effects of 1,25D for cultured human osteoblasts it is becoming clear that 1,25D
needs to converge with other signalling networks elicited by certain growth factors [38, 39] .
In our hands we consistently find that 1,25D per se enhances osteocalcin expression and an accompanying attenuation of cell growth, findings which would be expected for a pro-differentiating stimulus. However with regard to ALP, 1,25D has to act in concert with other stimuli, e.g., TGF [40] , epidermal growth factor [34] and LPA [22] to promote enzyme expression. The initial studies of Johanssen and colleagues [10] inspired us to examine whether 1,25D and LPA might co-operate to enhance YKL-40 production by MG63 cells. The impetus for this emerged from the culturing conditions utilised by Johanssen and colleagues in that first study [10] ; cells were treated with 1,25D in a medium supplemented with serum, a rich source of LPA, chiefly associated with the albumin fraction [20, 21] . It is clear from our studies that 1,25D and LPA do indeed converge to synergistically enhance YKL-40 mobilisation into the surrounding growth medium. Our findings go to help explain how 1,25D promotes osteoblast YKL-40 expression when these cells are exposed to a medium containing LPA. As has been alluded to already, little is known pertaining to the molecular control of YKL-40 expression. Using our model we therefore turned our attention to those intracellular mediators central to controlling osteoblast differentiation and fate and found that the expression of YKL-40 was sensitive to inhibitors targeting MEK, AP-1, Sp1 and STAT3.
In a previous study we reported that the expression of ALP in response to MG63 cells costimulated with LPA and 1,25D could be prevented using UO126, an inhibitor of MEK and therefore Erk phosphorylation/activation [22] . Similar results were obtained for cells cotreated with 1,25D and EGF [34] and 1,25D and colchicine [41] . Herein we now find that During the late stages of human macrophage differentiation, Rehli and colleagues [44] found YKL-40 to be markedly enhanced. In ascertaining the transcriptional regulation of YKL- . Herein we also find that as human osteoblasts progress to a more mature phenotype the mobilisation of YKL-40 in to the culture medium increases. We subsequently found that YKL-40 expression, consequent to co-treatment with LPA and 1,25D could be inhibited using Mithramycin A which prevents Sp1 promoter binding [45] . A key component for osteoblastogenesis is RUNX2, indeed mice nullizgous for Runx2 have defective osteoblast development [46] . Using murine MC3T3-E1
osteoblasts it has since been found that Sp1 expression is coupled to increased Runx2 gene expression whereas siRNA depletion of Sp1 reduces Runx2 expression and ALP [47] . How 1,25D and LPA converge in driving Sp1-dependent YKL-40 expression will necessitate further study but it is worth highlighting a report by Huang et al. [48] for how 1,25D might act; the VDR has been reported to activate P27 kip1 by physically binding to Sp1. Although the molecular mechanism by which VDR enhances Sp1-mediated transactivation remains to be resolved it is suggested that the VDR may increase the stability of Sp1-GC rich DNA interaction and resultant stimulation of target genes (which could include YKL-40 and ALP) via an Sp1 transactivation domain. Credence is given to this possibility given that both YKL-40 and ALP genes have Sp1 binding sites in their promoters [44, 49] .
In a previous study we also discovered that PMA and 1,25D co-operated to enhance MG63 osteoblast maturation, as supported by elevated ALP activity [34] . It has been known for over a quarter of a century, that the activation of PKC, by PMA, promotes osteoblast proliferation [50] . Interestingly, in our hands, when pro-mitogenic stimuli are combined with 1,25D, cell growth is attenuated and there is a concomitant enhancement of ALP production. The models we have utilised are representative of signal transduction "crosscoupling" wherein a pro-mitogenic stimulus, e.g., PMA, converges with a pro-differentiating steroid hormone [51] , which, in this particular case, is 1,25D. As with THP-1 cells [44] we now report that PMA and 1,25D synergistically increase YKL-40 production by MG63 cells.
We consistently find that MG63 maturation is accompanied by elevated expression of both ALP and that this now extends to YKL-40. To date these are the only two proteins known to be synergistically expressed consequent to co-treatment with 1,25D and selected growth factors and/or physical stimuli for any mammalian cell type.
Signal transducers and activators of transcription 3 (STAT3) are essential in mediating cell proliferation, differentiation and survival. Mutations in STAT3 result in Job syndrome characterised by skeletal and craniofacial anomalies [52] . Furthermore, the ability of autologous serum, a rich source of LPA, to promote osteoblast formation from human mesenchymal cells was found to be accompanied by enhanced STAT3
expression/phosphorylation/activation [53] . There is good evidence supporting an important role of STAT3 in YKL-40 expression in the context of IL-1, IL-6 and oncostatin M-stimulated human and murine astrocytes [37, 54] . We therefore set out to investigate .05) when compared to 2 days of culture. The co-treatment of MG63 cells with 5M LPA and 100nM 1,25D appeared to be the most effective combination for enhancing YKL-40 expression following a 48 hour culture period; p<0.01 versus 1.25M LPA; p<0.05 versus 2.5M LPA; p<0.005 versus 10M LPA. A similar trend for 5M LPA and 1,25D was observed following three days of culture wherein p<0.01 on comparison with 1.25M LPA and p<0.05 versus 2.5M LPA. The difference observed between 5M LPA and 1,25D and 10M LPA with 1,25D did not achieve statistical significance (p=0.11) after 72 hours of culture. B. In keeping with these temporal ELISA data a clear indication of demonstrable YKL-40 gene expression (~1000 fold normalised to GAPDH), as determined via qPCR, for MG63 cells co-exposed to 1,25D (100nM) and LPA (10M) for 48 hours. 
